BEARINGPOINT
20.6.2022 10:49:12 CEST | Business Wire | Press release
Management and technology consultancy BearingPoint has acquired I Care, a consultancy firm specializing in sustainability strategy development and environmental transition. With the integration, BearingPoint expands its offerings in the area of sustainability consulting and accelerates growth in its key consulting markets.
Established in 2008, I Care has more than 80 employees in France and Brazil and offers consulting services to public organizations, NGOs, private companies and financial institutions to respond to the risks and opportunities of the environmental transition. I Care distinguished itself by developing innovative methods and tools to quantify the performance of actors in the area of low-carbon transition and biodiversity footprint. By hybridizing scientific and strategy consulting skills, I Care has positioned itself as a key player in helping organizations define and implement environmental strategies.
“I Care’s capabilities and service offerings match perfectly with the needs of our clients in Europe. Moreover, we share the same culture of an entrepreneurial, holistic mindset and are trusted advisors for our clients. Together we look forward to becoming the key player in sustainable and environmental transformation consulting in France and entering selected markets internationally,” says Axelle Paquer, Regional Leader for France, Belgium, Luxemburg and Africa at BearingPoint.
BearingPoint , with more than 1,000 employees in France and 4,300 in Europe, has had a dedicated practice in sustainable development since 2010. This includes support for companies and public organizations in strategy, digital responsibility and the calculation of carbon emissions with its emissions calculator solution. BearingPoint is thus strengthening its ability to support clients in all aspects of their sustainable development strategies.
“I Care has a strong reputation for helping clients drive sustainability strategies and environmental transformation. Its proven practice and methodology combined with our transformation and digitalization capabilities will allow us to develop compelling new value propositions for our existing client portfolio in Europe, the US and China,” says Kiumars Hamidian, Managing Partner BearingPoint.
“Joining BearingPoint will enable I Care to accelerate our growth plans within a range of industry sectors in France and open the doors into more markets internationally. We are keen to leverage BearingPoint’s wider capabilities, notably in services such as emissions calculation and digital transformation, to benefit our existing client base. Becoming part of a leading international consulting organization opens up an opportunity to further increase our impact on society. ” says Guillaume Neveux, founder and CEO at I Care.
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information about BearingPoint, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
About I Care
I Care is a leading consulting company in the environmental field. Since 2008, I Care assists companies, financial institutions, and public organizations in their transition towards a low environmental impact society.
Combining expertise in strategy, finance, project management, and technical skills, its ambition is to provide clients with global solutions to their environmental challenges with the objective of moving to a sustainable economy. Thanks to its multidisciplinary approach between environmental expertises, consulting, research, the private, and public sectors, I Care has a wide range of skills providing a comprehensive response to the diverse needs in the field of sustainable development.
For more information about I Care, please visit:
Homepage: https://www.i-care-consult.com/
LinkedIn: https://www.linkedin.com/company/i-care-environnement/
Twitter: https://twitter.com/I_Care_Consult
View source version on businesswire.com: https://www.businesswire.com/news/home/20220620005150/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom